Meyer B H, Müller F O, Lötter M G, Iturralde M P, Grigoleit H G
S Afr Med J. 1981 Aug 8;60(6):243-4.
Penbutolol, a new beta-adrenoceptor blocker, was found to increase the glomerular filtration rate (GFR) significantly (16%) relative to placebo when administered orally in a dose of 40 mg daily for 7 consecutive days to healthy males. Measurements were performed after the seventh dose. In contrast, a single acute intravenous dose of penbutolol 4 mg did not influence the GFR, which was determined by means of a gamma counter after intravenous injection of technetium-99m diethylenetriaminepenta-acetic acid. Since penbutolol possesses moderate beta-adrenomimetic activity, it is postulated that the observed increase in the GFR after oral penbutolol could be due to increased cardiac output at rest.
喷布洛尔是一种新型β-肾上腺素能受体阻滞剂,在连续7天每天口服40mg剂量给健康男性时,相对于安慰剂,发现其可显著提高肾小球滤过率(GFR)(16%)。在第七剂给药后进行测量。相比之下,单次静脉注射4mg喷布洛尔对GFR无影响,GFR是在静脉注射锝-99m二乙三胺五乙酸后通过γ计数器测定的。由于喷布洛尔具有中等程度的β-拟肾上腺素活性,推测口服喷布洛尔后观察到的GFR升高可能是由于静息心输出量增加所致。